Introduction

35
Data from the EMPA-REG OUTCOME® clinical trial demonstrated that patients with type 2 36 diabetes mellitus (T2DM) and a high risk of cardiovascular disease who were randomized to 37 receive empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, on top of standard of 38 care had reduced risk of a primary outcome event (cardiovascular death, nonfatal myocardial 39 infarction, or nonfatal stroke) relative to those randomized to receive placebo. 1 
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Notably, the primary outcome benefit was driven by a significant reduction in cardiovascular 41 death; empagliflozin treatment also resulted in a reduced rate of hospitalization for heart 42 failure.
2 Please see the EMPA-REG OUTCOME results discussed in the article on 43 cardioprotection in T2DM by Lüscher and Paneni. 3 It had been thought previously that the 44 effect of empagliflozin on reducing hyperglycemia (and other cardiovascular risk factors) would 45 influence cardiovascular events via an impact on atherosclerosis. 4 However, the benefit of 46 empagliflozin treatment reported in EMPA-REG OUTCOME was observed earlier than would be 47 expected from any effect on atherosclerosis. In addition, the reduction in the occurrence of 48 heart failure hospitalization observed in the study had not been anticipated. It should be noted 49 that no imaging studies or substudies of specific patient populations were carried out during 50 EMPA-REG OUTCOME and biomarkers (eg, B-type natriuretic peptide, troponin T) were not 51 measured; thus, the characterization of cardiac status in the study population may be limited, 52 particularly with regard to the presence of subclinical heart failure, silent ischemia, or diabetic The benefits of empagliflozin observed during EMPA-REG OUTCOME were not limited to 55 cardioprotection, as an improvement in microvascular outcomes driven by renal events was 56 also reported with empagliflozin treatment. 6 It is possible that different mechanisms may have 57 accounted for the cardiac benefits versus those observed in the kidney, and that multiple 58 mechanisms may have contributed to the overall effect. Please see the article by Wanner that 59 discusses potential renal protective mechanisms associated with SGLT2 inhibitors. 7 Briefly, 60 these include reduced hyperglycemia, improved blood pressure control, reduced body weight, 61 and decreases in glomerular hyperfiltration and intraglomerular pressure. 8, 9 It is important to 62 note the link between cardiovascular and renal dysfunction in that chronic kidney disease is an 63 independent risk factor for cardiovascular disease and all-cause mortality. The diuretic potential of empagliflozin has been discussed as a possible contributory 249 mechanism to explain the reduction in heart failure hospitalizations observed during EMPA-REG 250 OUTCOME; 71 however, several caveats should be considered. versus that observed in EMPA-REG OUTCOME. 65 However, SGLT2 inhibitors differ from loop and 255 thiazide diuretics in that: 1) SGLT2 inhibitors do not lead to reflex sympathetic nervous system 256 activation (ie, no observed increase in heart rate despite blood pressure lowering); 2) thiazide 257 diuretics act on the distal tubule, whereas SGLT2 inhibitors act on the proximal tubule (ie, 258 proximal to the macula densa) and cause increased urinary sodium and chloride delivery to the 259 juxtaglomerular apparatus 65, 73 ; and 3) thiazide and loop diuretics are known to cause and this may result in reduced levels of aldosterone and decreased sympathetic nerve activity -267 either or both of which could reduce the risk of cardiovascular death and heart failure. 65 
268
The sodium excretion (natriuresis) associated with empagliflozin could also contribute to the 269 benefits seen in EMPA-REG OUTCOME: it could be the main cause of volume contraction and 270 could also be sustained over time. 
Conclusions
377
In the first publication of the results of EMPA-REG OUTCOME, the investigators stressed that 378 this was not a mechanistic study, and was designed to test the effects of empagliflozin 379 treatment rather than how the agent worked. All the mechanisms proposed to date to explain 380 the results of EMPA-REG OUTCOME are speculative, albeit based on the known effects of SGLT2 381 inhibitors and the changes observed during this study. In the initial discussion of the results, the 382 EMPA-REG OUTCOME study investigators speculated that the mechanism was probably 383 multidimensional. It is also possible that the rapid response observed in the study could be 384 20 explained by one mechanism and the long-term effects could involve separate mechanisms. 
